FDA Issues Warning Letter to Novo Nordisk Over Delayed Safety Reports for Ozempic and Victoza

Novo Nordisk receives FDA warning letter after 2025 Plainsboro inspection revealed failures in timely reporting serious side effects for drugs like Ozempic and Victoza. Company says no impact on production.